Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1998-11-23
2001-05-29
Hauda, Karen M. (Department: 1632)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S093100, C435S004000, C435S320100, C435S325000, C514S04400A, C536S023100
Reexamination Certificate
active
06239267
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genomics’, that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gne products as therapeutic targets is rapidly superceding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
SUMMARY OF THE INVENTION
The present invention relates to VANILREP1, in particular VANILREP1 polypeptides and VANILREP1 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of pain, chronic pain, neuropathic pain, postoperative pain, rheumatoid arhritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and inflammatory disorders, hereinafter referred to as “the Diseases”, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with VANILREP1 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate VANILREP1 activity or levels.
REFERENCES:
patent: 5232684 (1993-08-01), Blumberg et al.
patent: WO 99/09140 (1999-02-01), None
patent: WO 99/37675 (1999-07-01), None
Caterina et al. “The capsaicin receptor: a heat-activated ion channel in the pain pathway”, Nature, vol. 389, pp. 816-824 (1997).
Accession #T48002. Feb. 24, 1995.
Accession #AA321554. Apr. 18, 1997.
Copy of Partial EP Search Report. EP 98 20 3620 Jun. 1999.
Crystal RG. Science 270:404-410. 1995.*
Orkin SH and Motulsky AG. Report and Recommendations of the Panel to Assess the NIH investment in research of gene therapy, 1995.*
Verma IM and Somia N. Nature 389: 239-242. 1997.*
Adams et al (Genbank accession U91323 ,submitted Mar. 1997).*
Pearce A (Genbank Accession No AL020997, submitted Jan. 9, 1998).*
Gerken et al. (Genbank accession No. L29825, submitted May 23, 1995).*
Chiu (Genbank accession No AC002369 ,submitted Jul. 23, 1997).*
Leube RE et al. J Cell Biol 127:1589-1601. 1994.*
Caterina et al (Genbank accession No. AF029310, submitted Oct. 1997).
Davis John Beresford
Duckworth David Malcolm
Hayes Philip David
Meadows Helen Jane
Han William T.
Hauda Karen M.
King William T.
Ratner & Prestia
Shukla M.
LandOfFree
VANILREP1 polynucleotides and VANILREP1 polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with VANILREP1 polynucleotides and VANILREP1 polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VANILREP1 polynucleotides and VANILREP1 polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2550844